Рубрики Mesh:
Цистэктомия - вредные воздействия
Человек
Мужской
Новообразований рецидив местный - профилактика и контроль
Предстательной железы гиперплазия - осложнения
Предстательной железы гиперплазия - патология
Предстательной железы гиперплазия - хирургия
Риск
Трансуретральная резекция простаты - вредные воздействия
Мочевого пузыря новообразования - осложнения
Мочевого пузыря новообразования - патология
Мочевого пузыря новообразования - хирургия
Журнальная статья
Обзор
Alyaev Y.G. Yu G
Pshikhachev A.M.
Perekalina A.N.
Department of Urology, I.M. Sechenov First MSMU, Research Institute of Uronephrology and Human Reproductive Health.
The risk of bladder cancer in patients with prostatic hyperplasia and strategies to manage this combination
Текст визуальный электронный
Urologiia (Moscow, Russia : 1999)
№ 5 С. 115-118
2016
bladder cancer
bladder tumor
prostate adenoma
prostatic hyperplasia
transurethral resection
urothelial cancers
Статья
Обзор
Cystectomy adverse effects E04.950.774.150
Цистэктомия вредные воздействия E04.950.774.150
Humans B01.050.150.900.649.313.988.400.112.400.400
Человек B01.050.150.900.649.313.988.400.112.400.400
Male
Мужской
Neoplasm Recurrence, Local prevention & control C04.697.655 C23.550.727.655
Новообразований рецидив местный профилактика и контроль C04.697.655 C23.550.727.655
Prostatic Hyperplasia complications C12.100.500.565.500 C12.200.294.565.500
Prostatic Hyperplasia pathology C12.100.500.565.500 C12.200.294.565.500
Prostatic Hyperplasia surgery C12.100.500.565.500 C12.200.294.565.500
Предстательной железы гиперплазия осложнения C12.100.500.565.500 C12.200.294.565.500
Предстательной железы гиперплазия патология C12.100.500.565.500 C12.200.294.565.500
Предстательной железы гиперплазия хирургия C12.100.500.565.500 C12.200.294.565.500
Risk E05.318.740.600.800 G17.680.750 N05.715.360.750.625.700 N06.850.520.830.600.800
Риск E05.318.740.600.800 G17.680.750 N05.715.360.750.625.700 N06.850.520.830.600.800
Transurethral Resection of Prostate adverse effects E04.950.774.860.625.750
Трансуретральная резекция простаты вредные воздействия E04.950.774.860.625.750
Urinary Bladder Neoplasms complications C04.588.945.947.960 C12.050.351.937.820.945 C12.050.351.968.829.707 C12.200.758.820.968 C12.200.777.829.813 C12.900.820.945 C12.950.829.707 C12.950.983.945
Urinary Bladder Neoplasms pathology C04.588.945.947.960 C12.050.351.937.820.945 C12.050.351.968.829.707 C12.200.758.820.968 C12.200.777.829.813 C12.900.820.945 C12.950.829.707 C12.950.983.945
Urinary Bladder Neoplasms surgery C04.588.945.947.960 C12.050.351.937.820.945 C12.050.351.968.829.707 C12.200.758.820.968 C12.200.777.829.813 C12.900.820.945 C12.950.829.707 C12.950.983.945
Мочевого пузыря новообразования осложнения C04.588.945.947.960 C12.050.351.937.820.945 C12.050.351.968.829.707 C12.200.758.820.968 C12.200.777.829.813 C12.900.820.945 C12.950.829.707 C12.950.983.945
Мочевого пузыря новообразования патология C04.588.945.947.960 C12.050.351.937.820.945 C12.050.351.968.829.707 C12.200.758.820.968 C12.200.777.829.813 C12.900.820.945 C12.950.829.707 C12.950.983.945
Мочевого пузыря новообразования хирургия C04.588.945.947.960 C12.050.351.937.820.945 C12.050.351.968.829.707 C12.200.758.820.968 C12.200.777.829.813 C12.900.820.945 C12.950.829.707 C12.950.983.945
Journal Article V02.600
Журнальная статья V02.600
Review V02.600.500 V02.912
Обзор V02.600.500 V02.912
The combination of bladder cancer with benign prostatic hyperplasia (BPH) occurs in 5-27[%] of cases. The link between these diseases has not yet been closely investigated. The main role in the pathogenesis of bladder cancer combined with BPH is played by the residual urine and prolonged exposure of urothelium to the urine carcinogens. The choice of surgical treatment modality for the combination of non-muscle invasive bladder cancer and BPH is still a matter of debate. There is no consensus on the safety and appropriateness of simultaneous transurethral resection of the bladder and prostate in these patients. On one hand, opponents of simultaneous surgery suggest sustained exposure to carcinogens and the spread of tumor cells in a transurethral resection through the prostate wound surface in the blood and lymphatic vessels. On the other hand, supporters refer to studies and meta-analyzes showing that the simultaneous resection neither increases the recurrence rate of bladder cancer nor causes metastasis and tumor progression.